Tokai Pharmaceuticals may be trying to break into an increasingly crowded field of prostate cancer drugs, but Wall Street investors clearly like its chances to make an impact.
Cambridge, MA-based Tokai priced its IPO at $15 per share, the top of its projected range. It also sold 6.48 million in the offering, over a million more than it initially planned, raising a total of $97.2 million before discounts due to underwriters.
Help employers find you! Check out all the jobs and post your resume.
